CASE STUDY

How we helped rescue the recruitment in an

OVARIAN CANCER STUDY



OPTIMAPHARM

Background

Pivotal, randomized, open-label Medical Device study, for the treatment of recurrent Ovarian Cancer.



Challenge

- Study conducted during COVID-19 pandemic.
- The US and Canada did not recruit the planned number of patients.

Engagement

Optimapharm requested to take over this study in Europe for the following services:

- Project Management
- Feasibility
- Clinical Monitoring Services
- Ethics Committee submissions, Regulatory services
- Safety reporting
- TMF
- CTMS

Optimapharm solution

1. Selection of reliable sites, well prepared within limitations caused by the COVID-19 pandemic

2. Started the recruitment right after site activation

3. Selection of experienced CRAs

4. Involved more CRAs to deal with high recruitment and SDV backlog generated

Outcomes

Recruitment over-achieved by 117%

- 379 patients enrolled
- Last patient out achieved in May 2023

OPTIMAPHARM

We Deliver on Your Promises!

Explore our expertise!

RESOURCES

www.optimapharm.eu